This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.
Patients with histopathological and clinical (FIGO 2018) stage ⅠB2 ~II A2 cervical cancer.
Above the age of 18.
General status: ECOG score 0-2.
Be able to understand the research scheme, voluntarily participate in the study, and sign the informed consent.
Suffering from other malignant tumors.
Do not receive the specified treatment or change the treatment regimen before the disease progresses.
The study cannot be followed up according to the defined clinical follow-up period.
Unable to accept or provide CT or other designated therapeutic evaluation means.